Neurogene Inc.NASDAQ: NGNE

Neurogene to Participate in Upcoming Investor Conferences

· Issued by Neurogene Inc. via Business Wire

Summary by 6ix AI

Neurogene Inc., a clinical-stage company developing genetic medicines for rare neurological diseases, said its management will take part in fireside chats and investor meetings at two healthcare investor conferences.

Key details

  • Guggenheim 3rd Annual Healthcare Innovation Conference: fireside chat on Tuesday, November 10 at 10:30 a.m. ET.
  • Stifel 2026 Healthcare Conference: fireside chat on Wednesday, November 11 at 10:40 a.m. ET.
  • Live webcasts of the fireside chats will be available in the Investor Relations section of Neurogene's website under Events & Presentations, with replays available for a limited time.

6ix AI wrote this summary from the release below and checked it against the release.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences:

Guggenheim 3rd Annual Healthcare Innovation Conference
Format: Management will participate in a fireside chat and investor meetings
Date: Tuesday, November 10 at 10:30 a.m. ET

Stifel 2026 Healthcare Conference
Format: Management will participate in a fireside chat and investor meetings
Date: Wednesday, November 11 at 10:40 a.m. ET

Live webcasts of the fireside chats will be accessible from the Investor Relations section of Neurogene’s website under Events & Presentations, where replays of the events will also be available for a limited time.

About Neurogene
Neurogene (Nasdaq: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program, NGN-401, as a potential best-in-class, one-time treatment for Rett syndrome. For more information, visit neurogene.com or follow on LinkedIn.

View original source (Business Wire)Neurogene Inc. on 6ix

Story so far

Earlier from Neurogene

Later from Neurogene

All Neurogene news releases